28,941 Shares in Prothena Co. plc (NASDAQ:PRTA) Acquired by GSA Capital Partners LLP

GSA Capital Partners LLP bought a new position in shares of Prothena Co. plc (NASDAQ:PRTA) during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 28,941 shares of the biotechnology company’s stock, valued at approximately $484,000.

Other hedge funds have also recently bought and sold shares of the company. Signaturefd LLC boosted its position in Prothena by 182.1% during the second quarter. Signaturefd LLC now owns 1,337 shares of the biotechnology company’s stock worth $28,000 after acquiring an additional 863 shares during the last quarter. China Universal Asset Management Co. Ltd. raised its stake in Prothena by 63.7% during the third quarter. China Universal Asset Management Co. Ltd. now owns 10,344 shares of the biotechnology company’s stock worth $173,000 after purchasing an additional 4,026 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank raised its stake in Prothena by 13.1% during the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 10,236 shares of the biotechnology company’s stock worth $211,000 after purchasing an additional 1,186 shares during the period. ProShare Advisors LLC raised its stake in Prothena by 8.9% during the first quarter. ProShare Advisors LLC now owns 11,346 shares of the biotechnology company’s stock worth $281,000 after purchasing an additional 932 shares during the period. Finally, Teachers Retirement System of The State of Kentucky raised its stake in Prothena by 26.0% during the first quarter. Teachers Retirement System of The State of Kentucky now owns 14,039 shares of the biotechnology company’s stock worth $348,000 after purchasing an additional 2,895 shares during the period. Institutional investors and hedge funds own 97.08% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on PRTA shares. Oppenheimer cut their price target on shares of Prothena from $66.00 to $62.00 and set an “outperform” rating on the stock in a research note on Wednesday, August 14th. Royal Bank of Canada cut their price target on shares of Prothena from $28.00 to $24.00 and set a “sector perform” rating on the stock in a research note on Friday, August 9th. Bank of America cut their target price on shares of Prothena from $33.00 to $31.00 and set a “neutral” rating on the stock in a research note on Tuesday, October 1st. HC Wainwright reissued a “buy” rating and issued a $84.00 target price on shares of Prothena in a research note on Wednesday, November 13th. Finally, StockNews.com downgraded shares of Prothena from a “hold” rating to a “sell” rating in a research note on Tuesday. One analyst has rated the stock with a sell rating, two have assigned a hold rating and five have given a buy rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $61.86.

Prothena Trading Up 4.0 %

PRTA opened at $14.05 on Wednesday. The company has a fifty day simple moving average of $17.92 and a 200 day simple moving average of $20.20. The firm has a market cap of $756.03 million, a price-to-earnings ratio of -5.67 and a beta of 0.16. Prothena Co. plc has a twelve month low of $13.22 and a twelve month high of $41.54.

Prothena (NASDAQ:PRTA) last released its quarterly earnings results on Tuesday, November 12th. The biotechnology company reported ($1.10) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.18) by $0.08. The business had revenue of $0.97 million during the quarter, compared to analyst estimates of $1.22 million. Prothena had a negative net margin of 98.86% and a negative return on equity of 24.19%. The business’s revenue was down 98.9% on a year-over-year basis. During the same period last year, the business earned $0.38 EPS. On average, analysts forecast that Prothena Co. plc will post -2.29 earnings per share for the current fiscal year.

About Prothena

Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, for the treatment of Parkinson’s disease and other related synucleinopathies which is in Phase IIb clinical trial; NNC6019 that is in Phase lI clinical trial for the treatment of ATTR amyloidosis; and BMS-986446 and PRX012, which is in Phase I clinical trial for the treatment of Alzheimer’s disease.